Welcome to Adheron Therapeutics:
Shaping the Future of Biology and Therapeutics
Adheron Therapeutics is a groundbreaking biotechnology company revolutionizing the understanding and treatment of autoimmune, inflammatory, and fibrotic diseases. By leveraging cutting-edge research and the expertise of globally recognized scientists, we are paving the way for innovative therapies that improve lives and transform healthcare.
Our Mission: Innovation Meets Impact
At Adheron Therapeutics, we believe in harnessing the power of science to address the world’s most pressing medical challenges. Our mission is to bridge the gap between foundational research and real-world applications, delivering impactful therapies through collaboration, innovation, and scientific excellence.
About Adheron Therapeutics
Scientific Founders
Our foundation lies in the groundbreaking discoveries of Dr. Michael Brenner, MD, a distinguished scientist and professor at Harvard Medical School. His work in antigen presentation, inflammatory pathways, and autoimmune mechanisms forms the cornerstone of our research programs.
Experienced Leadership
Led by Hari Kumar, PhD, an industry veteran with over 25 years in pharmaceutical development, our leadership team brings unmatched expertise in drug development, strategic partnerships, and biotech innovation.
Our Cutting-Edge Programs
Cadherin-11: A Game-Changing Discovery
Cadherin-11 (Cad-11) is at the heart of our research programs. This adhesion molecule, expressed on fibroblasts in various tissues, plays a critical role .
Rheumatoid Arthritis: Cad-11 interactions exacerbate joint inflammation and damage.
Fibrotic Disorders: Emerging evidence links Cad-11 to pathological fibrosis in the lungs, skin, and other organs.
Our therapeutic approach focuses on developing Cadherin-11 inhibitors to disrupt these harmful pathways and offer relief to patients with chronic, debilitating diseases.
Pipeline Innovations
Our pipeline is designed to tackle the most complex biological challenges:
Fibrosis Therapies
Targeting mechanisms underlying tissue scarring.
Autoimmune Solutions: Addressing immune-mediated diseases with precision therapies.
Oncology Research: Exploring Cad-11’s role in tumor microenvironments.
Learn more about our programs and therapeutic targets.
Partnering Opportunities
At Adheron Therapeutics, collaboration is the cornerstone of innovation. We actively seek partnerships with academic institutions, biotech firms, and pharmaceutical companies to accelerate the development and delivery of transformative therapies.
Why Partner with Us?
- Access to Breakthrough Research: Collaborate on cutting-edge Cadherin-11 discoveries.
- Experienced Team: Work alongside industry leaders in research and development.
- Accelerated Development: Leverage our expertise to bring therapies to market faster.
News & Events
Recent Highlights
Phase 1 Success: Promising results from our Cadherin-11 clinical trials.
Leadership Growth: Welcoming new senior executives to drive our mission forward.
Research Breakthroughs: Expanding Cadherin-11’s therapeutic potential.
Why Choose Adheron Therapeutics?
Groundbreaking Science: Transformative research on Cadherin-11 and fibrotic pathways.
Unmatched Expertise: Led by pioneers in rheumatology, immunology, and drug development.
Collaborative Vision: Building partnerships that drive innovation and deliver results.
Patient-Centered Approach: Focused on therapies that improve quality of life and address unmet medical needs.
Join the Adheron Therapeutics Community